The main functions of Platinib (Pujihua) capsules and their efficacy in tumor treatment

1. Overview of Drugs

Pralsetinib is an orally selectable RET tyrosine kinase inhibitor, mainly used to treat solid tumors related to RET gene fusion or mutation. RET (Rearranged in Transforming Tyrosine Kinase) is a type of key driver gene that undergoes gene rearrangements or point mutations in certain tumors, including non-small cell lung cancer (NSCLC), papillary thyroid carcinoma and other RET fusion-related solid tumors. RETGene abnormalities can lead to abnormal activation of downstream signaling pathways, such as RAS/MAPK, PI3K/AKT, thereby promoting the proliferation and survival of tumor cells. Platinib inhibits tumor growth by highly selectively inhibiting RET tyrosine kinase activity and blocking abnormal signaling.

Platinib capsules are oral preparations that patients can take conveniently at home. It is usually recommended once a day. The dosage is adjusted individually by a doctor based on body weight, liver and kidney function, and specific conditions.

2. Main efficacy and mechanism of action

The main effect of Platinib is targeted inhibition of RET driven tumor signaling pathways. Its mechanism of action includes:

1.Inhibition of RETtyrosine kinase activity: Platinib can highly selectively bind to the RET protein's ATP binding site and block its autophosphorylation, thereby inhibiting tyrosine kinase activity and preventing tumor cell proliferation signaling.

2.Downstream signaling pathway blocking: RET is inhibited, MAPK/ERK, < The activity of downstream signaling pathways such as span>PI3K/AKT and JAK/STAT decreases, reducing cell cycle protein expression and anti-apoptotic signals, causing tumor cells to enter a state of apoptosis or growth arrest.

3.High selectivity reduces side effects: Compared with multi-target TKI, platinib is highly selective for RET and has less inhibitory effect on other kinases such as VEGFR, so it has a lower impact on the cardiovascular system or blood pressure and has better safety.

In summary, platinib plays a comprehensive role in inhibiting tumor growth, blocking signal transduction and inducing apoptosis by precisely targeting RET abnormalities.

3. Clinical efficacy in tumor treatment

1.Non-small cell lung cancer (NSCLC)

RETfusions are driver mutations in approximately 1–2% of patients with advanced NSCLC. Clinical studies have shown that Platinib has significant efficacy in RETfusion-positive NSCLC patients: the overall response rate (ORR) can reach 60% and most patients experience tumor shrinkage within weeks to months. Progression-free survival (PFS) has been significantly prolonged, and some patients have also shown certain effects on brain metastases.

2.Papillary thyroid carcinoma (PTC) and RET mutation-related thyroid cancer

RETMutations or fusions are common in advanced papillary thyroid cancer. Platinib can significantly reduce tumor size and relieve thyroid cancer-related symptoms, such as neck pressure and dyspnea, in such patients. Studies have shown that the overall response rate can exceed 70% and the efficacy can be maintained for a long time, providing a new treatment option for patients who are inoperable or resistant to radioactive iodine.

3.OthersRETFusion-related solid tumors

Although non-small cell lung cancer and thyroid cancer are the main indications, Platinib has also shown certain efficacy in rare solid tumors such as RET fused cholangiocarcinoma and gastrointestinal tumors, providing targeted treatment options for patients with rare RET driven tumors.

In addition, platinib showed remaining efficacy in patients resistant to previous chemotherapy or multi-targeted TKI, making it a RETDriving second- and third-line treatment options for cancer.

4. Clinical application and usage suggestions

Platinib must be used in medical institutions with RET gene testing capabilities to determine whether patients have RET fusions or mutations to ensure that targeted therapy is accurate and effective. Regular monitoring is required during use:

1. Blood routine, liver and kidney function: evaluate drug metabolism and potential toxicity;

2.Cardiovascular indicators: Although the side effects are low, you still need to pay attention to changes in blood pressure and electrocardiogram;

3.Tumor imaging examination: Regularly review tumor size and changes in lesions to evaluate efficacy;

4.Adverse reaction management: Common side effects include mild to moderate increase in blood pressure, leukopenia and mild gastrointestinal discomfort, most of which can be alleviated by adjusting the dose or symptomatic treatment.

Overall, platinib capsules show good efficacy and controllable safety in RET fusion or mutation-related solid tumors by precisely inhibiting RET tyrosine kinase activity, providing patients with a reliable targeted therapy option.

Reference link:https://www.drugs.com